(Q37965613)

English

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

scientific article published on January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Andreas Pfützner

2

object named as

Andreas Pfützner

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Thomas Forst

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

0 references

publication date

1 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

101-110

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Stemming the global obesity epidemic: what can we learn from data about social and economic trends?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Standards of medical care in diabetes--2011.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Is glycemic control improving in U.S. adults?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

The gap between guidelines and practice in the treatment of type 2 diabetes A nationwide survey in Norway

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Glucose control and vascular complications in veterans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

The evolving place of incretin-based therapies in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Gut peptides and type 2 diabetes mellitus treatment

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.642863

21 January 2018

Identifiers

10.1517/14656566.2012.642863

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37965613&oldid=1735115509"